Evidence map›Paper›PMID 18664560›Full record

Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2008

Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up.

I J Diel, A Jaschke, E F Solomayer, C Gollan, G Bastert, C Sohn, F Schuetz

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 6 pooled it
14.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 6 syntheses or guidelines pooled it, 226 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Bisphosphonates and other bone agents for breast cancer.The Cochrane database of systematic reviews · 2017
    Pooled it
  5. Pooled it
  6. NCCN Task Force Report: Bone Health in Cancer Care.Journal of the National Comprehensive Cancer Network : JNCCN · 2009
    Guideline
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in Germany.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Article
  19. Review
  20. Role of Bisphosphonates in Breast Cancer Therapy.Current treatment options in oncology · 2019
    Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

I J DielDepartment of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany. diel@cgg-mannheim.de
A Jaschke
E F Solomayer
C Gollan
G Bastert
C Sohn
F Schuetz
Heidelberg University · DEUniversity of Mannheim · DEUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdding oral clodronate to postoperative adjuvant breast cancer therapy significantly improves disease-free survival (DFS) and overall survival (OS). Long-term follow-up data from the prospective, randomized, controlled study are reported. PATIENTS AND

methodsPatients with primary breast cancer received clodronate 1600 mg/day for 2 years or no treatment along with standard adjuvant breast cancer treatment.

resultsAnalysis of 290 of 302 patients demonstrated that a significant improvement in OS was maintained in the clodronate group at a median follow-up of 103 +/- 12 months; 20.4% of patients in the clodronate group versus 40.7% of control group patients (P = 0.04) died during the 8.5 years following primary surgical therapy. Significant reductions in the incidence of bony and visceral metastases and improvement in duration of DFS at 36- and 55-month follow-up periods were no longer seen with clodronate.

conclusionThese long-term survival data extend the survival advantage reported in previous studies with oral clodronate in breast cancer.

Indexed as

Administration, OralAdultAgedAntineoplastic AgentsBone Density Conservation AgentsBone MarrowBone NeoplasmsBreast NeoplasmsChemotherapy, AdjuvantClodronic AcidCombined Modality TherapyDisease-Free SurvivalFemaleFollow-Up StudiesHumansIncidenceAntineoplastic AgentsBone Density Conservation AgentsClodronic Acid

Identifiers

PMID18664560
PMCPMC2733118
OpenAlexW2155937162

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.